Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes
Unknown status
Columbia University
N/A
2007-06-01
The investigators are conducting a study of asthma patients who use fluticasone with
salmeterol (Advair) or any other combination of an inhaled corticosteroid (ICS) and a long
acting beta agonist (LABA) to manage their asthma symptoms.
Participants begin the study by continuing to use fluticasone with salmeterol or substituting
fluticasone with salmeterol for their current ICS/LABA medication at their regular dose or
the comparable dose(all study medications are provided) for a six-week period. Patients are
then separated into 2 groups: one group is asked to use fluticasone (Flovent), the other to
use fluticasone with salmeterol , twice daily over a 16-week period (patients will need to be
seen monthly during this time). Neither study personnel nor patients will know which drug is
being used.
Patients are also asked to use a peak flow meter and record their daily results on a form,
along with the number of puffs they use of their rescue inhaler each day. They also record
any changes in asthma medications and information on any asthma episodes.
The investigators hypothesize that there are certain patients with asthma who will do better
when a long acting beta agonist is removed from their maintenance asthma medications.
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
Completed
ALK-Abelló A/S
Phase 3
2007-11-01
The purpose of the study is to investigate the efficacy and safety of a grass sublingual
tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis
with or without asthma.
Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2007-11-01
The purpose of the study is to investigate the efficacy and safety of a grass sublingual
tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis
with or without asthma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
